I"!<p>Results of the Phase 2 Consortium trial of ibrutinib in relapsed or refractory follicular lymphoma (<a href="https://clinicaltrials.gov/show/NCT01849263?link_type=CLINTRIALGOV&amp;access_num=NCT01849263&amp;sso-checked=true">NCT01849263</a>) have been published online through the journal Blood. Genomic analysis led by Griffith lab postdoc, Felicia Gomez, identified CARD11 mutations as predictors of poor treatment response.</p>

<div class="row">
    <div class="small-12 columns">
        <img src="/assets/img/news/CARD11_figure_8.png" />
    </div>
</div>
<p><br />
Read the article: [<a href="https://www.ncbi.nlm.nih.gov/pubmed/29074501">PubMed</a>] [<a href="http://www.bloodjournal.org/content/early/2017/10/25/blood-2017-09-804641?papetoc=&amp;sso-checked=true">Journal website</a>]</p>
:ET